Pentheroudakis, G.

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 3,421

ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: A report from the ESMO Precision Medicine Working Group

Pascual, J., Attard, G., Bidard, F.-C., Curigliano, G., De Mattos-Arruda, L., Diehn, M., Italiano, A., Lindberg, J., Merker, J. D., Montagut, C., et al. (2022) · Annals of Oncology

Cancer Genomics and DiagnosticsBRCA gene mutations in cancer

Cited by 783

Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS

Yoshino, T., Arnold, D., Taniguchi, H., Pentheroudakis, G., Yamazaki, K., Xu, R.-H., Kim, T. W., Ismail, F., Tan, I. B., Yeh, K.-H., et al. (2018) · Annals of Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 573

Artificial Intelligence for Predictive Biomarker Discovery in Immuno-Oncology: A Systematic Review

Prelaj, A., Miskovic, V., Zanitti, M., Trovo, F., Genova, C., Viscardi, G., Rebuzzi, S. E., Mazzeo, L., Provenzano, L., Kosta, S., et al. (2024) · Annals of Oncology

Cancer Immunotherapy and BiomarkersRadiomics and Machine Learning in Medical Imaging

Cited by 340

ESMO guidance for reporting oncology real-world evidence (GROW)

Castelo-Branco, L., Pellat, A., Martins-Branco, D., Valachis, A., Derksen, J. W. G., Suijkerbuijk, K. P. M., Dafni, U., Dellaporta, T., Vogel, A., Prelaj, A., et al. (2023) · Annals of Oncology

Meta-analysis and systematic reviewsClinical practice guidelines implementation

Cited by 247

Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes

Pentheroudakis, G., Kotoula, V., De Roock, W., Kouvatseas, G., Papakostas, P., Makatsoris, T., Papamichael, D., Xanthakis, I., Sgouros, J., Televantou, D., et al. (2013) · BMC Cancer

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 111

ESMO guidance on the use of Large Language Models in Clinical Practice (ELCAP)

Wong, E. Y. T., Verlingue, L., Aldea, M., Franzoi, M. A., Umeton, R., Halabi, S., Harbeck, N., Indini, A., Prelaj, A., Romano, E., et al. (2025) · Annals of Oncology

Artificial Intelligence in Healthcare and EducationElectronic Health Records Systems

Cited by 44

The Prognostic Role of Ephrin A2 and Endothelial Growth Factor Receptor Pathway Mediators in Patients With Advanced Colorectal Cancer Treated With Cetuximab

Strimpakos, A., Pentheroudakis, G., Kotoula, V., De Roock, W., Kouvatseas, G., Papakostas, P., Makatsoris, T., Papamichael, D., Andreadou, A., Sgouros, J., et al. (2013) · Clinical Colorectal Cancer

Colorectal Cancer Treatments and StudiesHER2/EGFR in Cancer Research

Cited by 27

Gemcitabine combined with the mTOR inhibitor temsirolimus in patients with locally advanced or metastatic pancreatic cancer. a hellenic cooperative oncology group phase I/II study

Karavasilis, V., Samantas, E., Koliou, G.-A., Kalogera-Fountzila, A., Pentheroudakis, G., Varthalitis, I., Linardou, H., Rallis, G., Skondra, M., Papadopoulos, G., et al. (2018) · Targeted Oncology

Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and Treatment

Cited by 27